Amgen quarterly profit tops expectations despite sales decline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Amgen (AMGN) PT Lowered to $193 at Morgan Stanley Following 3Q
October 26, 2017 9:25 AM EDTMorgan Stanley lowered its price target on Amgen (NASDAQ: AMGN) to $193.00 (from $196.00) while maintaining a Overweight rating following the company's 3Q release. Total revenues were slightly above ($5.77B vs. $5.74B cons), as were COGS (+$10M) and SG&A (+$20M), with R&D... More
